CDKN2A (Wild-Type) Oropharyngeal Carcinoma clinical trials
16 active Oropharyngeal Carcinoma trials that test for CDKN2A (Wild-Type) in their eligibility criteria. Describe your situation to see which ones look like a fit.
- Evaluating a Decreased Dose of Radiation Therapy to the Elective Neck for the Treatment of HPV-Related Oropharyngeal Cancer, ENLIGHT Trial
- A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer
- De-escalation of Adjuvant Radiation for Low-Risk HPV Oropharyngeal Cancers
- Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma
- A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)
- pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer
- Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
- Treatment De-Escalation for Favorable Prognosis Human Papilloma Virus (HPV) or p16-Positive Oropharyngeal Cancer Receiving Definitive Radiotherapy
- Dose Adjusted Chemoradiotherapy in HPV-Associated Oropharynx Cancer of the Elderly
- Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer
- Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer
- Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer
- Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
- Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
- Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
- Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer
← All Oropharyngeal Carcinoma trials
Guides for people searching for a trial
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.